RIGL Rigel Pharmaceuticals Inc.

2.49
+0.03  (+1%)
Previous Close 2.46
Open 2.47
Price To Book 6.07
Market Cap 417,350,150
Shares 167,610,502
Volume 1,463,607
Short Ratio
Av. Daily Volume 1,704,594
Stock charts supplied by TradingView

NewsSee all news

  1. Rigel Pharmaceuticals Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today provided a business update, including preliminary product revenue and total TAVALISSE® (fostamatinib disodium

  2. Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at

  3. Rigel Announces Chief Commercial Officer Transition

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), today announced that Eldon Mayer has resigned from his position as chief commercial officer effective December 23,

  4. Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the

  5. Rigel to Present at Jefferies 2019 London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released April 3, 2018. Primary endpoint not met.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Approved April 17, 2018.
Tavalissetm (Fostamatinib)
Immune Thrombocytopenic Purpura (ITP)
Phase 3 data due mid-2021.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 1 trial has been completed - noted October 23, 2019.
R835
Autoimmune and inflammatory diseases

Latest News

  1. Rigel Pharmaceuticals Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today provided a business update, including preliminary product revenue and total TAVALISSE® (fostamatinib disodium

  2. Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at

  3. Rigel Announces Chief Commercial Officer Transition

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), today announced that Eldon Mayer has resigned from his position as chief commercial officer effective December 23,

  4. Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the

  5. Rigel to Present at Jefferies 2019 London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company

  6. Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition

    SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets has been accepted for two

  7. Rigel Announces Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today reported financial results for the third quarter ended September 30, 2019, including sales of TAVALISSE®

  8. Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2019 financial results after market close on Tuesday, November 5,

  9. Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call

    SOUTH SAN FRANCISCO, Calif., Oct. 23, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today provided a business update that will be discussed in more detail on the company's investor and analyst call

  10. Rigel Secures Credit Facility for Up to $60 Million

    SOUTH SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has entered into a $60 million term loan credit facility with MidCap Financial ("MidCap"). At

  11. Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a

  12. Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to